HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.

AbstractINTRODUCTION:
High-risk neuroblastoma is a deadly disease; poor prognosticators are MYCN-amplification and TERT-overexpression. We hypothesized that Gene Set Enrichment Analysis (GSEA) could identify pathways associated with MYCN-amplification and that inhibition of these pathways could decrease tumor growth.
METHODS:
We analyzed the Neuroblastoma-Kocak dataset (GSE45547, n = 649) and identified pathways associated with MYCN-amplification. Inhibitors were selected from upregulated gene sets for in vitro cytotoxicity testing using ST16-patient-derived primary neuroblastoma cells and in vivo testing using orthotopic ST16-patient-derived xenografts (PDX) in mice. Tumor volume was measured with ultrasound and tumor sections examined after H&E staining.
RESULTS:
GSEA identified significantly overexpressed gene sets in MYCN-amplified tumors including MYC targets, cell cycle mitotic genes, TERT associated genes, loss of RB1 gene sets, and E2Fs targets. Several genes were potential Bromodomain-containing protein 4 (Brd4) targets, making Brd4 inhibitors - JQ1, AZD5153 - and cyclin-dependent kinase (Brd4's binding partner) inhibitors - dinaciclib - potential therapeutic agents. JQ1 and dinaciclib were synergistic in inducing cytotoxicity in vitro. Dinaciclib-AZD5153 in vivo decreased tumor size compared to control, and increased tumor lymphocyte infiltration and necrosis on histology.
CONCLUSIONS:
GSEA is a powerful approach to identify upregulated genes and potential therapeutic targets. Dinaciclib-AZD5153 combination therapy can be effective against MYCN-amplified and TERT-overexpressing neuroblastoma tumors.
AuthorsLauren Wood, Min Huang, Jasmine Zeki, Miao Gong, Jordan Taylor, Hiroyuki Shimada, Bill Chiu
JournalJournal of pediatric surgery (J Pediatr Surg) Vol. 56 Issue 7 Pg. 1199-1202 (Jul 2021) ISSN: 1531-5037 [Electronic] United States
PMID33838899 (Publication Type: Journal Article)
CopyrightCopyright © 2021. Published by Elsevier Inc.
Chemical References
  • BRD4 protein, human
  • Cell Cycle Proteins
  • MYCN protein, human
  • N-Myc Proto-Oncogene Protein
  • Nuclear Proteins
  • Transcription Factors
  • Cyclin-Dependent Kinases
Topics
  • Animals
  • Cell Cycle Proteins (genetics)
  • Cell Line, Tumor
  • Cyclin-Dependent Kinases
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mice
  • N-Myc Proto-Oncogene Protein (genetics, metabolism)
  • Neuroblastoma (drug therapy, genetics)
  • Nuclear Proteins (genetics, metabolism)
  • Transcription Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: